chemieunternehmen.com

Evotec announced today that the Company has entered a target and drug discovery partnership with Boehringer Ingelheim, focusing on induced pluripotent stem cell (“iPSC”)-based disease modelling for ophthalmologic disorders. Millions of people are affected by vision-related diseases worldwide, and there is a high unmet need for novel therapeutic solutions.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-ipsc-based-drug-discovery-partnership-with-boehringer-ingelheim-in-ophthalmology-6136

Evotec SE announced today that the Company has entered into a drug discovery collaboration with Eli Lilly and Company in the field of metabolic diseases with a focus on kidney diseases and diabetes. The collaboration leverages Evotec’s extensive experience and track record of delivering in the field of metabolic diseases, as well as its unique and extensive kidney disease patient database. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-lilly-enter-into-drug-discovery-collaboration-in-metabolic-diseases-6132

Evotec partner Celmatix, a biotechnology company focused on ovarian biology, today announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec. The milestone was triggered by Evotec and Bayer AG advancing a drug programme, centered around a novel Celmatix-identified drug target, into hit-identification. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partner-celmatix-achieves-milestone-for-pcos-drug-programme-6134

Evotec SE announced today that the Company has expanded its neurodegeneration collaboration with Bristol Myers Squibb with the initiation of discovery and development efforts regarding a new strategy to tackle neurodegenerative diseases including Alzheimer’s through a novel approach to targeted protein degradation. Evotec receives payments totalling US$ 15 m from Bristol Myers Squibb. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-neuroscience-collaboration-with-bristol-myers-squibb-to-include-new-targeted-protein-degradation-approach-6130

Evotec SE announced today that the Company has been selected by the German Federal Ministry of Education and Research (“BMBF”) to receive a grant for the development of EVT075, a potential first-in-class immunomodulatory therapy against COVID 19. Evotec is one of three companies receiving a highly competitive grant as part of a new initiative by the BMBF to support the clinical development of novel therapeutic candidates against COVID-19. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-eur-75-m-grant-for-development-of-covid-19-therapeutic-6128

Evotec SE today announced that the Company has received a US$ 18 m grant from the Bill & Melinda Gates Foundation for the integrated discovery and development of a novel, first-in-class programme to accelerate progress in the area of women’s health and contraceptive technology, leveraging Evotec’s integrated R&D platform. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-us-18-m-grant-for-womens-health-6126